Recent

% | $
Quotes you view appear here for quick access.

Pozen, Inc. Message Board

  • davidparkland davidparkland Nov 28, 2011 11:57 AM Flag

    company will end up with 110 mil and

     

    no debt meaning about $3.66 per share in cash..so am I correct to conclude that the company is selling for its cash value per share..kinda of odd and underpriced..or am I incorrect..help

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I also find it a bit weird that the stock is trading only a few pennies above what *will* be cash value at year end:

      "Monetizing this portion of the U.S. Treximet royalty unlocks its inherent value and significantly improves our balance sheet without dilution of existing shareholders. This enables us to negotiate with potential partners for PA32540 from a much stronger position and to continue to execute our strategic plan," said Dr. John R. Plachetka, Chairman, President and Chief Executive Officer. "With the completion of this transaction, we now expect to end 2011 with greater than $110 million, or approximately $3.67 per share, in cash, cash equivalents and short-term investments."

      From the same PR:

      "This agreement has no effect on any future royalties from MT400 that might originate from sales of the product outside of the United States."

      Does that mean Treximet isn't approved by the EMA? Thought it was...nope, doesn't look like it, just checked GSK's 2010 annual report and it shows only sales in the US. WTF are they waiting for?!? Have they even applied for approval to the EMA?

    • Yes - worried if PA is a dud. If PA is dead, it means over $50 mln flushed to the drain.

      But so far, I think PA may get approved.

    • There must something else going on. The response today is underwhelming. I wonder if this is a short candidate. I will be watching it. It seems like it should be higher, unless there is something else.

 
POZN
5.940.00(0.00%)Feb 5 4:00 PMEST